By empowering researchers to detect data quality issues in real-time, Risk-Based Quality Management (RBQM) and Risk-Based Monitoring (RBM) have proven their value during the race for a COVID-19 vaccine in which trials required the processing of huge volumes of data from dozens of global sites. RBQM is now driving significant changes throughout clinical research, helping to speed up the drug development pathway without compromising data quality while ensuring early risk detection remains a priority. Patrick Hughes at CluePoints outlines why RBQM is the future-proofed solution to managing risk for the entire clinical trial life cycle – and how the benefits for clinical research can be fully unlocked.